HCPCS J3520 is officially defined as "Edetate disodium, per 150 mg." HCPCS J3520 is referenced in 7 tracked payer policy changes from Sentara Health Plans, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3520 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Chelation therapy is considered medically necessary when based on blood levels and used to treat chronic iron overload due to blood transfusions or nontransfusion-dependent thalassemia, extreme conditions of metal toxicity, lead poisoning, Wilson's disease, emergency treatment of hypercalcemia, or control of ventricular arrhythmias or heart block associated with digitalis toxicity. Off-label applications, including atherosclerosis, Alzheimer disease, arthritis, multiple sclerosis, diabetes, autism, and Parkinson disease, are considered investigational. The 08/06/2026 review added Parkinson disease to the investigational list, and the 10/01/2026 update added ICD-10 codes R78.72 and Z77.013 to the code reference.
Aetna considers outpatient IV antibiotic therapy medically necessary for Lyme disease only when the clinical presentation is compatible with the disease and supported by two-tier serologic testing. Once Lyme disease is definitively diagnosed, an initial 4-week course of outpatient IV antibiotic therapy is medically necessary for persistent Lyme arthritis after failing a 4-week course of oral antibiotics, for moderate-to-severe cardiac or neurologic involvement, and for specified cases in pregnant women, and one repeat 4-week course is medically necessary with objective evidence of relapse, progression of organ damage, or a new focus or type of organ damage. Aetna considers IV antibiotic therapy for early Lyme disease, additional antibiotic therapy for post-treatment persistently fatigued patients, and a range of listed tests and treatments experimental, investigational, or unproven.
Deferoxamine mesylate is considered medically necessary for transfusional iron overload in members with chronic anemia when the pretreatment serum ferritin is greater than 1000 mcg/L, for aluminum toxicity in members undergoing dialysis, and for hereditary hemochromatosis when phlebotomy is not an option or the member had an unsatisfactory response to phlebotomy, and it must be prescribed by or in consultation with a hematologist or nephrologist. Other chelation therapy is considered medically necessary for conditions including aceruloplasminemia, biliary cirrhosis, Cooley's anemia, cystinuria, Diamond-Blackfan anemia, sickle cell anemia, Wilson's disease, secondary hemochromatosis, and heavy metal toxicity when symptoms are suggestive and toxicity is confirmed by laboratory testing. Chelation therapy for cancer, cardiovascular disease, neurodegenerative diseases, autism, ADHD, and mercury toxicity from dental amalgam fillings is considered experimental, investigational, or unproven.
Independence Blue Cross reissued MA07.016c on 08/06/2025 to reaffirm its continuing position on intravenous chelation therapy coverage. The policy adds 12 new ICD-10 codes related to gadolinium toxicity (T56.821A through T56.824S) and clarifies coverage criteria for medically necessary chelation therapy while designating off-label uses as experimental/investigational.
Independence Blue Cross reissued Policy 07.00.02j on intravenous chelation therapy, adding 12 new ICD-10 diagnosis codes for gadolinium toxicity (T56.821A through T56.824S) to the covered indications. The policy maintains existing coverage for chelation therapy for iron overload, metal poisoning, lead toxicity, Wilson's disease, digoxin toxicity, and hypercalcemia, with no changes to covered agents, billing codes, or clinical criteria.
Aetna's Clinical Policy Bulletin 0020 on injectable medications was last reviewed March 5, 2026 and is scheduled for its next review January 14, 2027, but the page does not list what changed. It covers injectables when no appropriate oral alternative exists, excludes experimental drugs and performance-enhancing steroids, and notes that contraceptive injectables, infertility injectables and travel immunizations are excluded under some benefit plans.
Watch J3520
Get one email when a payer policy names J3520, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J3520
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J3520 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.